Risperidone: Refining the Tools to Treat Schizophrenia

Logan, Jeanette; Finley, Paul R.

doi:10.1111/j.1527-3458.1999.tb00103.x

Cited by 2 publications

(1 citation statement)

References 52 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An extensive review of its pharmacology and clinical use has been published in 1990 (123).Remoxipride belongs to the atypical/novel antipsychotic or neuroleptic group of drugs, as opposed to the typical/classical antipsychotics. This broad group of novel antipsychotics includes drugs such as clozapine, olanzapine, raclopride, risperidone and ritanserin (6,56,69,74,99,105,118). What makes an antipsychotic drug atypical?…”

mentioning

confidence: 99%

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist

Nadal

2001

CNS Drug Reviews

View full text Add to dashboard Cite

Remoxipride is a substituted benzamide that acts as a weak but very selective antagonist of dopamine D 2 receptors. It was introduced by Astra (Roxiam ® ) at the end of the eighties and was prescribed as an atypical antipsychotic. This article reviews its putative selective effects on mesolimbic versus nigrostriatal dopaminergic systems. In animals, remoxipride has minimal cataleptic effects at doses that block dopamine agonist-induced hyperactivity. These findings are predictive of antipsychotic activity with a low likelihood of extrapyramidal symptoms. Remoxipride also appears to be effective in more recent animal models of schizophrenia, such as latent inhibition or prepulse inhibition. In clinical studies, remoxipride shows a relatively low incidence of extrapyramidal side effects and its effects on prolactin release are short-lasting and generally mild. The clinical efficacy of remoxipride is similar to that of haloperidol or chlorpromazine. Although its clinical use was severely restricted in 1993, due to reports of aplastic anemia in some patients receiving remoxipride, this drug has been found to exhibit relatively high selectivity for dopamine D 2 receptors making remoxipride an interesting tool for neurochemical and behavioral studies.

show abstract

mentioning

confidence: 99%

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist

Nadal

2001

CNS Drug Reviews

View full text Add to dashboard Cite

show abstract

Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs. Part 2

Hermecz

2003

Advances in Heterocyclic Chemistry

View full text Add to dashboard Cite

Risperidone: Refining the Tools to Treat Schizophrenia

Cited by 2 publications

References 52 publications

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist

Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs. Part 2

Contact Info

Product

Resources

About

Risperidone: Refining the Tools to Treat Schizophrenia

Cited by 2 publications

References 52 publications

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2 Receptor Antagonist

Recent Development in the Chemistry of Pyrido-oxazines, Pyrido-thiazines, Pyrido-diazines and Their Benzologs. Part 2

Contact Info

Product

Resources

About

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist

Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D₂ Receptor Antagonist